GAFFX
Price
$86.88
Change
+$0.68 (+0.79%)
Updated
Sep 8 closing price
Net Assets
332.38B
SPECX
Price
$34.91
Change
+$0.48 (+1.39%)
Updated
Sep 8 closing price
Net Assets
4.15B
Interact to see
Advertisement

GAFFX vs SPECX

Header iconGAFFX vs SPECX Comparison
Open Charts GAFFX vs SPECXBanner chart's image
American Funds Growth Fund of Amer F3
Price$86.88
Change+$0.68 (+0.79%)
VolumeN/A
Net Assets332.38B
Alger Spectra A
Price$34.91
Change+$0.48 (+1.39%)
VolumeN/A
Net Assets4.15B
GAFFX vs SPECX Comparison Chart in %
Loading...
View a ticker or compare two or three
VS
GAFFX vs. SPECX commentary
Sep 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GAFFX is a Buy and SPECX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
GAFFX has more cash in the bank: 332B vs. SPECX (4.15B). GAFFX pays higher dividends than SPECX: GAFFX (0.59) vs SPECX (0.00). GAFFX was incepted earlier than SPECX: GAFFX (9 years) vs SPECX (56 years). SPECX (1.52) is less costly to investors than GAFFX (0.30). SPECX is a more actively managed with annual turnover of: 49.26 vs. GAFFX (25.00). SPECX has a lower initial minimum investment than GAFFX: SPECX (1000) vs GAFFX (1000000). SPECX annual gain was more profitable for investors over the last year : 42.78 vs. GAFFX (22.13). GAFFX return over 5 years is better than : 46.66 vs. SPECX (22.32).
GAFFXSPECXGAFFX / SPECX
Total Expense Ratio0.301.5220%
Annual Report Gross Expense Ratio0.301.5220%
Fund Existence9 years56 years-
Gain YTD16.66422.75073%
Front LoadN/A5%-
Min. Initial Investment10000001000100,000%
Min. Initial Investment IRAN/AN/A-
Net Assets332B4.15B7,992%
Annual Yield % from dividends0.590.00-
Returns for 1 year22.1342.7852%
Returns for 3 years54.2899.7154%
Returns for 5 years46.6622.32209%
Returns for 10 yearsN/A96.45-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DMAC7.161.02
+16.61%
DiaMedica Therapeutics
CTSO0.980.02
+1.74%
Cytosorbents Corp
HALO75.850.92
+1.23%
Halozyme Therapeutics
CHARU10.82N/A
N/A
Charlton Aria Acquisition Corp
TXG13.93-0.03
-0.21%
10x Genomics